Viking Therapeutics (VKTX) Non-Current Deffered Revenue (2015 - 2018)

Viking Therapeutics has reported Non-Current Deffered Revenue for 4 years, with the latest figure at $12000.0 in Q4 2018.

• Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $12000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $12000.0 (changed N/A YoY) and the FY2018 annual result came in at $12000.0, changed N/A from the prior year.
• Non-Current Deffered Revenue improved to $12000.0 in Q4 2018 per VKTX's latest filing, from $6054.0 in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $31239.0 in Q4 2015 and troughed at $6054.0 in Q2 2017.
• A 4-year average of $18706.3 and a median of $19149.0 in 2015 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2016 and 2017: Non-Current Deffered Revenue grew 6.93% in 2016, then plunged 75.44% in 2017.
• Over 4 years, Non-Current Deffered Revenue stood at $31239.0 in 2015, then tumbled by 47.8% to $16307.0 in 2016, then sank by 62.87% to $6054.0 in 2017, then surged by 98.22% to $12000.0 in 2018.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $12000.0, $6054.0, and $10862.0 for Q4 2018, Q2 2017, and Q1 2017 respectively.